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CARBAMAZEPINE AND OTHER ANTI-EPILEPTIC DRUGS 
IN THE AQUATIC ENVIRONMENT
KARBAMAZEPINA I INNE LEKI 
O DZIAŁANIU PRZECIWPADACZKOWYM 
W ŚRODOWISKU WODNYM
A b s t r a c t
This paper is part of a series of publications discussing the prevalence of pharmaceuticals in the aquatic 
environment and the effectiveness of their removal and degradation during wastewater treatment processes. 
The paper discusses the problem of the presence of carbamazepine and other anti-epileptic drugs. The authors 
reviewed the basic characteristic parameters of these compounds, and based on the analysed literature data, 
the problem of anti-epileptic drugs, mainly carbamazepine, in the aquatic environment. Carbamazepine appears 
to be exceptionally persistent at municipal wastewater treatment plants as has been confirmed by current studies 
on its elimination and degradation, as well as reports on its presence in surface water, groundwater and even 
drinking water. The latest studies demonstrated highly effective removal of carbamazepine during oxidation 
processes. The application of these methods in real life situations should enable the effective protection of the 
aquatic environment.
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The aim of the study is to present issues concerning the presence of anti-epileptic 
compounds  (in  particular,  carbamazepine)  in  wastewater  as  well  as  in  surface  water, 
groundwater and drinking water. Pharmaceuticals and specimens used by humans are usually 
converted into hydrophilic forms in the liver and only in this form are the metabolites excreted 
by  the  kidneys;  this  is  the major  path  of  drug  removal  from  the  human  body. However, 
compounds that are not absorbed from the gastrointestinal tract or that are easily soluble 
electrolytes may leave the body unchanged [2]. These are discharged to the sewer system, 
and are then transported to municipal wastewater treatment plants where, at least in theory, 
compounds  that may  pollute  the  environment  (i.e.  drugs)  are  removed  from wastewater. 
The actual removal efficiency of some specific pharmaceuticals is very low and sometimes 
close to zero (e.g. carbamazepine).
Since pharmaceuticals are not effectively removed from wastewater, they are discharged 
with the plant effluent into rivers (receivers), from where they may penetrate to groundwater 
or  be  taken  up  by  the  water  treatment  plants.  Prior  to  2007,  more  than  90  different 
pharmaceuticals  had  been  identified  all  over  the world  –  they were  found  in  seas,  lakes, 
rivers, groundwater, sediments and soils [3]. Although concentrations of these compounds 
found in rivers or drinking water are very low in comparison to the threshold concentrations 
that show negative effects on aquatic organisms, this does not relieve us from the obligation 
to produce drinking water of a high quality, free from pharmaceuticals.
2. Characteristics of anti-epileptic drugs
Anti-epileptic pharmaceuticals have been used mainly in the treatment of epilepsy. 
This neurological disorder occurs when too many neurons become excited in the central 
nervous system. The most common and most widely used anti-epileptic drug is carbamazepine. 
T a b l e  1
Characteristics of selected anticonvulsants [30‒35]
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Despite its widespread use, the research points out some negative effects this compound 
has on the human body ‒ these include a lowered content of leukocytes and platelets in the 
blood and the risk of fetal distress. It has also been known that carbamazepine is toxic for 
some algae, bacteria,  invertebrates  and fish  [5]. Other  agents of  this group are diazepam, 
lorazepam, phenobarbital, valproate and carbamazepine ‒ these are included on the WHO 
Model List  of Essential Medicines  [36]. Table 1 presents  some  important  information on 
anti-epileptic drugs.
3. The presence of pharmaceuticals in the environment
Potential sources of pharmaceuticals in the environment are presented in Fig. 1 [24].
Since anti-epileptic drugs are used in the treatment of epilepsy and anxiety, hospital and 
household wastewater are their main sources in the environment;  through them, the drugs 
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are transported to the wastewater treatment plants. Studies in Belgium on the detection 
of,  for  example,  carbamazepine  (CBZ)  and  diazepam  (DIA)  in  raw wastewater,  showed 
that  their concentrations were 227-1028 ng/l and 1‒9 ng/l, respectively. The analysis was 




of  pharmaceuticals:  CBZ  =  0.30‒1.17  mg/l,  DIA  =  0.002‒0.010  mg/l  and  lorazepam 
= 0.17‒0.25 mg/l. Based on these reports, it can be concluded that among the antiepileptic 
drugs, it is carbamazepine that appears in the wastewater in the highest concentrations.
Studies  on  the  degradation  efficiency  of  numerous  pharmaceuticals  [7]  demonstrated 







The above conclusion means that wastewater which carries CBZ, is discharged 
to the receiving waters causing their contamination. Tests conducted on river water 
downstream  from  the  effluent  discharge  [8],  showed  up  to  330  ng/l  of CBZ  in  a  sample 
Fig. 1. Sources and pathways of pharmaceutical pollution in water and soil
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taken  35.7  kilometers  downstream  from  the  discharge  point.  Other  publications  stated 
that  the  average CBZ  concentrations  in  natural waters were:  in Great Britain  ‒  251  ng/l 
(max 684 ng/l) [19], in Italy ‒ 345 ng/l [16] and even up to 1110 ng/l in the national park 
of Spain [5]. CBZ is not adsorbable on soil [11]; therefore, its presence in surface water may 
lead to its further penetration to groundwater. Also, for this reason, the utilisation of sludge 
from wastewater treatment plants contaminated with CBZ can lead to groundwater pollution 
and the accumulation of this drug in plants.
There have been reports on the presence of carbamazepine in groundwater in Germany 
(Halle,  2‒83  ng/l  [18],  Leipzig  about  90  ng/l  [17]  and  also  much  higher  concentrations 
of  900  ng/l  [21],  and  even  2325  ng/l  [15]),  France  10.4  ng/l  [28]  and  the  US  ‒  up  to 
420  ng/l  [15]. However,  CBZ may  be  present  in  the  environment,  not  only  in  its  parent 
form but also as metabolites, which are found in groundwater at concentrations ranging from 
0.9 to 39.9 ng/l [4, 9, 14].
The concentrations of pharmaceuticals found in surface water and groundwater are 
sometimes several orders of magnitude lower than threshold concentrations which show 
negative effects on aquatic organisms. However, it cannot be clearly stated that such low 
concentrations  do  not  pose  any hazards  to  living organisms when  subjected  to  long-term 
exposure.  Currently,  there  are  no  reliable  studies  confirming  whether  pharmaceuticals, 
even at low concentrations, may or may not have any effects on the human body. If water 
at the water treatment plants contains pharmacologically active compounds, including 
carbamazepine, one should effectively eliminate these compounds as a preventive measure.
Despite the use of advanced water treatment methods, there have been cases when 
carbamazepine was detected  in drinking water. A  study conducted  in  Japan  showed CBZ 
concentrations  of  12‒25  ng/l  [23]. An  extremely  high  concentration  of  CBZ  in  drinking 
water  (over  600 ng/l) was  reported  in Canada;  the  authors  attributed  it  to  an  exceptional 
stability of this compound [10]. On the other hand, studies carried out in Spain confirmed 
the  reduction  of  CBZ  concentrations  below  the  acceptable  detection  limits  (0.03  ng/l) 
thus demonstrating that carbamazepine may be effectively removed at the water treatment 
plant [1].
4. Removal and degradation
Taking into account the fact that wastewater from hospitals and households are the greatest 
sources of anticonvulsants, some appropriate methods of the elimination or degradation 
of these compounds should be considered. In the case of hospital wastewater, some kind 
of pre-treatment before discharge into the sewage system could reduce the levels of these 
compounds that reach wastewater treatment plants. However, for household sewage, that 
option is not possible since it would be difficult to employ such a pretreatment unit in every 
home.
Investigations on using an additional ozone stage, prior to the anaerobic digestion 
of sewage sludge [6], has not shown a significant improvement in the degradation efficiency 
of the studied pharmaceuticals (including diazepam). However, in the case of carbamazepine, 
60%  degradation  in  thermophilic  conditions  was  observed;  anaerobic  digestion  that  was 
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not preceded by ozonation was ineffective. Additionally, membrane processes, including 
nanofiltration,  which  shows  only  a  small  retention  of  CBZ  [20],  are  ineffective  in  the 
removal of carbamazepine from the wastewater treatment plant effluent. Currently, research 
is  conducted on  the  use  of  ferrate  (VI)  for  the  degradation of  pharmaceuticals,  including 
carbamazepine  [29]. The  results  confirmed  the  successful  degradation of CBZ depending 
on  the  initial  concentrations  and  pH;  for  a  concentration  of  100  µg/l,  45%  removal was 
observed at pH = 6 and 99% removal at pH = 9;  for a concentration of 10 µg/l,  removal 
of  up  to  99%  was  observed,  regardless  of  pH.  As  part  of  the  work,  the  authors  also 
identified  carbamazepine  oxidation  products,  which  in  the  case  of  using  this  method  on 
a large scale would allow for monitoring and controlling the process efficiency.
5. Conclusions










as these solutions are promising.
6. References
[1] Azzouz A., Ballesteros E., Influence of seasonal climate differences on the pharmaceutical, 
hormone and personal care product removal efficiency of a drinking water treatment plant, 
Chemosphere, Vol. 93, 2013, 2046-2054.
[2] Balcerzak W., Rezka,P., Occurrence of anti-cancer drugs in the aquatic environment and 
efficiency of their removal – the selected issues, Technical Transactions, 1-Ś/2014, 11-18.
[3] Buntner D., Żabczyński S., Miksch K., Usuwanie farmaceutyków ze ścieków, Chemik, Vol. 60, 
2007, 120-124.
[4] Cabeza Y., Candel, L., Ronen D., Teijon G., Monitoring the occurrence of emerging contaminants 
in treated wastewater and groundwater between 2008 and 2010. The Baix Llobregat (Barcelona, 
Spain), Hazardous Materials, Vol. 239–240, 2012, 32-39.
[5]  Camacho-Munoz  D.,  Martin  J.,  Santos  J.L.,  Aparicio  I.,  Alonso  E.,  Occurrence, temporal 
evolution and risk assessment of pharmaceutically active compounds in Doñana Park (Spain), 
Journal of Hazardous Materials, Vol. 183, 2010, 602-608.
[6]  Carballa M., Manterola G., Larrea L., Ternes T., Omil F., Lema J.M., Influence of ozone pre­ 
-treatment on sludge anaerobic digestion: Removal of pharmaceutical and personal care 
products, Chemosphere, Vol. 67, 2007, 1444-1452.
117
[7]  Carballa  M.,  Omil  F.,  Ternes  T.,  Lema  J.M.,  Fate of pharmaceutical and personal care 
products (PPCPs) during anaerobic digestion of sewage sludge, Water Research, Vol. 41, 2007,  
2139-2150.
[8]  Dong B., Kahl A., Cheng L., Vo H., Ruehl S., Zhang T., Snyder S., Saez A.E., Quanrud D., 
Arnold R.G., Fate of trace organics in a wastewater effluent dependent stream, Science of the 
Total Environment, Vol. 518–519, 2015, 479-490.
[9] Huntscha  S.,  Singer H.P., McArdell  C.S.,  Frank C.E.,  Hollender  J., Multiresidue analysis of 
88 polar organic micropollutants in ground, surface and wastewater using online mixed-bed 
multilayer solid-phase extraction coupled to high performance liquid chromatography-tandem 
mass spectrometry, Journal of Chromatography A, Vol 1268, 2012, 74-83.
[10]  Kleywegt S., Pileggi V., Yang P., Hao C., Zhao X., Rocks C., Tchach S., Cheung P., Whitehead B., 
Pharmaceuticals, hormones and bisphenol A in untreated source and finished drinking water 
in Ontario, Canada ­ occurrence and treatment efficiency, Science of the Total Environment, 
Vol. 409, 2011, 1481-1488.
[11] Kodesova R., Grabic R., Kocarek M., Klement A., Golovko O., Fer M., Nikodem A., Jaksik O., 
Pharmaceuticals’ sorptions relative to properties of thirteen different soils, Science of the Total 
Environment, Vol. 511, 2015, 435-443.
[12] Kosma C.I., Lambropoulou D.A., Albanis T.A., Occurrence and removal of PPCPs in municipal 
and hospital wastewaters in Greece, Journal of Hazardous Materials, Vol. 179, 2010, 804-817.
[13] Langford K.H., Thomas K.V., Determination of pharmaceutical compounds in hospital effluents 
and their contribution to wastewater treatment works, Environment International, Vol. 35, 2009, 
766-770.
[14] Lopez-Serna R., Jurado A., Vazquez-Sune E., Carrera J., Petrovic M., Barcelo D., Occurrence 
of 95 pharmaceuticalss and transformation products in urban groundwaters underlying the 
metropolis of Barcelona, Spain, Environmental Pollution, Vol. 174, 2013, 305-315.
[15]  Luo Y., Guo W., Ngo H.H., Nghiem L.D., Hai F.I., Zhang J., Liang S., Wang X.C., A review 
on the occurrence of micropollutants in the aquatic environment and their fate and removal 
during wastewater treatment, Science of the Total Environment, Vol. 473-474, 2014, 619-641.
[16]  Meffe R., de Bustamante I., Emerging organic contaminants in surface water and groundwater: 
A first overview of the situation in Italy,  Science  of  the Total  Environment, Vol.  481,  2014,  
280-295.
[17]  Musolff A., Leschik S., Moder M., Strauch G., Reinstorf F., Schirmer M., Temporal and spatial 
patterns of micropollutants in urban receiving waters, Environmental Pollution, Vol. 157, 2009, 
3069-3077.
[18]  Osenbruck K., Glaser H.R., Knoller K., Weise S.M., Moder M., Wennrich R., Sources and 
transport of selected organic micropollutants in urban groundwater underlying the city of Halle 
(Saale), Germany, Water Research, Vol. 41, 2007, 3259-3270.
[19] Petrie B., Barden R., Kasprzyk-Hodern,B., A review on emerging contaminants in wastewaters 
and the environment: Current knowledge, understudied areas and recommendations for future 
monitoring, Water Research, Vol. 72, 2015, 3-27.
[20]  Rohricht M., Krisam  J., Weise U., Kraus U.R., During R.A., Elimination of carbamazepine, 
diclofenac and naproxen from treated wastewater by nanofiltration, Clean Soil Air Water, 
Vol. 37, 2009, 638-641.
[21] Sacher F., Lange F.T., Brauch H.J., Blankenhorn I., Pharmaceuticals in groundwaters: analytical 
methods and results of a monitoring program in Baden-Wurttemberg, Germany,  Journal 
of Chromatography A, Vol. 938, 2001, 199-210.
[22] Shao  B.,  Chen  D.,  Zhang  J., Wu Y.,  Sun  C., Determination of 76 pharmaceutical drugs by 
liquid chromatography–tandem mass spectrometry in slaughterhouse wastewater,  Journal 
of Chromatography A, Vol. 1216, 2009, 8312-8318.
118
[23] Simazaki D., Kubota R., Suzuki T., Akiba M., Nishimura T., Kunikane S., Occurrence of selected 
pharmaceuticals at drinking water purification plants in Japan and implications for human 
health, Water Research, Vol. 76, 2015, 187-200.
[24] Stuart M., Lapworth D., Crane E., HartA., Review of risk from potential emerging contaminants 
in UK groundwater, Science of the Total Environment, Vol. 416, 2012, 1-21.
[25]  Tarcomnicu I., van Nuijs A.L.N., Simons W., Bervoets L., Blust R., Jorens P.G., Neels H., Covaci 
A., Simultaneous determination of 15 top­prescribed pharmaceuticals and their metabolites 
in influent wastewater by reversed­phase liquid chromatography coupled to tandem mass 
spectrometry, Talanta, Vol. 83, 2011, 795-803.
[26]  Verlicchi P., Al Aukidy M., Galletti A., Petrovic M., Barcelo D., Hospital effluent ­ Investigation 
of the concentrations and distribution of pharmaceuticals and environmental risk assessment, 
Science of the Total Environment, Vol. 430, 2012, 109-118.
[27]  Verlicchi P., Al Aukidy M., Zambello E., Occurrence of pharmaceutical compounds in Urban 
wastewater: removal, mass load and environmental risk after a secondary treatment - a review, 
Science of the Total Environment, Vol. 429, 2012, 123-155.
[28]  Vulliet E., Cren-Olive C., Screening of pharmaceuticals and hormones at the regional scale, in 
surface and groundwaters intended to human consumption, Environmental Pollution, Vol. 159, 
2011, 2929-2934.
[29] Zhou Z., Jiang J.Q., Treatment of selected pharmaceuticals by ferrate (VI): Performance, kinetic 
studies and identification of oxidation products,  Journal  of  Pharmaceutical  and  Biomedical 
Analysis, Vol. 106, 2015, 37-45.
[30]  Carbamazepine, www.drugbank.ca/drugs/DB00564, online: 31.05.2015.
[31] Diazepam, www.drugbank.ca/drugs/DB00829, online: 31.05.2015.
[32] Lorazepam, www.drugbank.ca/drugs/DB00186, online: 31.05.2015.
[33] Phenytoin, www.drugbank.ca/drugs/DB00252, online: 31.05.2015.
[34] Phenobarbital, www.drugbank.ca/drugs/DB01174, online: 31.05.2015.
[35]  Valproic acid, www.drugbank.ca/drugs/DB00313, online: 31.05.2015.
[36]  WHO Model List of Essential Medicines, www.who.int/iris/bitstream/10665/93142/1/EML_18_
eng.pdf, online: 31.05.2015.
